news
Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014
7 August 2014 | By Novo Nordisk
7% sales growth in local currencies driven by Levemir® and Victoza®...
List view / Grid view
Novo Nordisk
news
Xultophy® (IDegLira) receives positive opinion from the Committee for Medicinal Products for Human Use for use in adults with type 2 diabetes
29 July 2014 | By Novo Nordisk
Novo Nordisk announced that the Committee for Medicinal Products for Human Use under the European Medicines Agency has adopted a positive opinion for Xultophy®...
news
Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo
23 June 2014 | By Novo Nordisk
New data from the phase 3a SCALE™ Diabetes trial were presented at the International Congress of Endocrinology and the Endocrine Society’s meeting, investigating the effect of liraglutide 3 mg in adults...
news
New phase 3 study shows efficacy and safety of Victoza® for the treatment of type 2 diabetes in adults with moderate renal impairment
16 June 2014 | By Novo Nordisk
Data from a new phase 3 study demonstrated that once-daily Victoza® (liraglutide) provided greater glycaemic control versus placebo with no worsening of renal function in adults with type 2 diabetes and moderate renal impairment...
news
Analysis: 6,000 new jobs in Novo Nordisk create a further 15,000 jobs in Denmark
11 June 2014 | By Novo Nordisk
Up to 2022, Novo Nordisk expects to hire 6,000 new employees in Denmark, half of whom will work within research and development...
news
Novo Nordisk to present 63 abstracts at 74th Annual American Diabetes Association Scientific Sessions in San Francisco, CA
10 June 2014 | By Novo Nordisk
Novo Nordisk, will unveil 63 abstracts containing safety and efficacy data from our class-leading portfolio of diabetes products at the 74th Annual Scientific Sessions of the American Diabetes Association...
news
Phase 3a data from largest trial with liraglutide 3 mg demonstrated significantly greater weight loss versus placebo for adults with obesity
16 May 2014 | By Novo Nordisk
Results from the SCALE™ Obesity and Pre-diabetes phase 3a trial will be presented on 16 May, 2014 for the first time at the 23rd Annual Congress of the American Association of Clinical Endocrinologists...
news
NovoEight® provides long-term reduction of bleeding in people with haemophilia A
12 May 2014 | By Novo Nordisk
Novo Nordisk announced new phase 3 interim data from its guardian™2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade...
news
Increased operating profit in local currencies by 15% in the first quarter of 2014
1 May 2014 | By Novo Nordisk
7% sales growth in local currencies driven by Levemir® and Victoza®...
news
Novo Nordisk invests 550 million Danish kroner in new purification pilot plant in Denmark
14 March 2014 | By Novo Nordisk
Novo Nordisk is increasing its drug development capacity by investing 550 million Danish kroner in a new research and development facility in Bagsværd, Denmark...
news
Election of employee representatives to the Board of Directors of Novo Nordisk A/S
27 February 2014 | By Novo Nordisk
The employees of Novo Nordisk A/S have conducted the election of employee representatives to the Board of Directors of Novo Nordisk A/S...
news
Novo Nordisk launches its shortest needle: NovoFine® Plus, compatible with all major pen devices
20 January 2014 | By Novo Nordisk
Canada is the first country to make NovoFine® Plus available and will be followed by several other countries during 2014 and 2015...
news
Novo Nordisk reported to the police by the Danish Financial Supervisory Authority for violating disclosure obligation
10 December 2013 | By Novo Nordisk
The reporting relates to the company’s receipt of a Complete Response Letter from the US Food and Drug Administration...
news
Ryzodeg® offers improved glycaemic control with significantly lower rates of hypoglycaemia compared to biphasic insulin aspart 30 in adults with type 2 diabetes
3 December 2013 | By Novo Nordisk
Data presented at the World Diabetes Congress of the International Diabetes Federation show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia...
news
IDegLira demonstrates superior glycaemic control and weight loss with a low rate of hypoglycaemia for patients uncontrolled on basal insulin
3 December 2013 | By Novo Nordisk
New phase 3 data from the investigational therapy IDegLira were presented at the World Diabetes Congress of the International Diabetes Federation...
